Marinus Pharmaceuticals Stock Alpha and Beta Analysis
| MRNS Stock | USD 0.33 0.01 3.13% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Marinus Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Marinus Pharmaceuticals over a specified time horizon. Remember, high Marinus Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Marinus Pharmaceuticals' market risk premium analysis include:
Beta 1.67 | Alpha (0.69) | Risk 12.64 | Sharpe Ratio (0.05) | Expected Return (0.67) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Marinus |
Marinus Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Marinus Pharmaceuticals market risk premium is the additional return an investor will receive from holding Marinus Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Marinus Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Marinus Pharmaceuticals' performance over market.| α | -0.69 | β | 1.67 |
Marinus Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Marinus Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Marinus Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Marinus Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Marinus Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Marinus Pharmaceuticals shares will generate the highest return on investment. By understating and applying Marinus Pharmaceuticals stock market price indicators, traders can identify Marinus Pharmaceuticals position entry and exit signals to maximize returns.
Marinus Pharmaceuticals Return and Market Media
The median price of Marinus Pharmaceuticals for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 1.42 with a coefficient of variation of 52.98. The daily time series for the period is distributed with a sample standard deviation of 0.63, arithmetic mean of 1.18, and mean deviation of 0.57. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Marinus Pharmaceuticals Market Outperform Rating Reiterated at JMP Securities | 09/26/2024 |
2 | Disposition of 1660 shares by Mayleben Timothy M of Marinus Pharmaceuticals subject to Rule 16b-3 | 10/10/2024 |
3 | Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY Titration Regimens | 10/15/2024 |
4 | Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment | 10/18/2024 |
5 | Marinus tanks after late stage trial for treatment of seizures fails to meet main goal | 10/24/2024 |
6 | GSK invests 800M in manufacturing Amgen sets small discount for Eylea biosimilar | 10/25/2024 |
7 | Marinus Pharma earnings missed by 0.01, revenue fell short of estimates | 11/12/2024 |
8 | US1.86 Thats What Analysts Think Marinus Pharmaceuticals, Inc. Is Worth After Its Latest Results | 11/15/2024 |
About Marinus Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Marinus or other stocks. Alpha measures the amount that position in Marinus Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2023 | 2024 (projected) | Days Sales Outstanding | 75.78 | 44.75 | 42.51 | PTB Ratio | 8.15 | 34.85 | 36.59 |
Marinus Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Marinus Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Marinus Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Marinus Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Marinus Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Marinus Pharmaceuticals' management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Marinus Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.